StockData
EDSANasdaqPharmaceutical PreparationsFiscal year ends September 30

Edesa Biotech, Inc.

Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$2.78+0.21 (+8.17%)

Close on Oct 19, 2026

Market cap
$25.04M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Dec 11, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q3 FY2026
Ended Jun 30, 2026
Aug 13, 2026After market close–$-0.60–
Q2 FY2026
Ended Mar 31, 2026
May 14, 2026After market close–$-0.49–
Q1 FY2026
Ended Dec 31, 2025
Feb 13, 2026After market close–$-0.28–
Q4 FY2025
Ended Sep 30, 2025
Dec 12, 2025After market close–––
Q3 FY2025
Ended Jun 30, 2025
Aug 8, 2025After market close–$-0.25–
Q2 FY2025
Ended Mar 31, 2025
May 14, 2025After market close–$-0.30–
Q1 FY2025
Ended Dec 31, 2024
Feb 14, 2025After market close–––
Q4 FY2024
Ended Sep 30, 2024
Dec 13, 2024After market close–––
Q3 FY2024
Ended Jun 30, 2024
Aug 9, 2024After market close–$-0.52–
Q2 FY2024
Ended Mar 31, 2024
May 10, 2024After market close–$-0.58–
Q1 FY2024
Ended Dec 31, 2023
Feb 9, 2024After market close–$-0.54–

Press releases

Announcements Edesa Biotech filed with the SEC